Testing the safety and efficacy of the PD-L1 antibody durvalumab

Bookmark and Share
Published: 6 Jun 2016
Views: 2048
Dr Christophe Massard - Institut Gustave Roussy, Paris, France

Dr Massard talks to ecancertv at ASCO 2016, discussing a phase I/II dose escalation and dose expansion study evaluating the safety and efficacy of durvalumab, a modified human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, in solid tumours including urothelial bladder cancer.